These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 668390)

  • 61. Profiling of uremic ultrafiltrate using high resolution gas chromatography-mass spectrometry - identification of 6 polyphenols.
    Niwa T; Maeda K; Ohki T; Saito A; Kobayashi S; Asada H; Kobayashi K
    Clin Chim Acta; 1980 Nov; 108(1):113-9. PubMed ID: 7449132
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Amino acid composition of uremic middle and low molecular weight retention products.
    Bazilinski N; Shaykh M; Ahmed S; Musiala T; Williams RH; Poulos A; Dubin A; Dunea G
    Adv Exp Med Biol; 1987; 223():197-204. PubMed ID: 3447436
    [TBL] [Abstract][Full Text] [Related]  

  • 63. All products of proglucagon are elevated in plasma from uremic patients.
    Orskov C; Andreasen J; Holst JJ
    J Clin Endocrinol Metab; 1992 Feb; 74(2):379-84. PubMed ID: 1730817
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Amino acid metabolism in the chronically uremic rat.
    Swendseid ME; Wang M; Vyhmeister I; Chan W; Siassi F; Tam CF; Kopple JD
    Clin Nephrol; 1975 Jun; 3(6):240-6. PubMed ID: 237643
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Correlation of a colorimetric and a HPLC method for the determination of serum hippuric acid concentrations in uremia.
    Vanholder R; De Smet R; Schoots A; Ringoir S
    Nephron; 1988; 49(2):164-8. PubMed ID: 3380232
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Endogenous ligand(s) decrease drug--protein binding in uremic sera: a fluorescence probe study.
    Robertz GM; Dengler HJ
    Klin Wochenschr; 1983 Jul; 61(13):649-53. PubMed ID: 6688447
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Association of adiponectin with cardiovascular events in diabetic and non-diabetic hemodialysis patients.
    Elokely A; Shoukry A; Ghonemy TA; Atia M; Amr G
    Saudi J Kidney Dis Transpl; 2012 Jul; 23(4):736-42. PubMed ID: 22805386
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Studies on uremic toxins; structure-activity correlation in H-Asp(Gly)-OH.
    Abiko T; Kumikawa M; Dazai S; Takahashi H; Ishizaki M; Sekino H
    Biochem Biophys Res Commun; 1978 May; 82(2):707-15. PubMed ID: 666867
    [No Abstract]   [Full Text] [Related]  

  • 69. Increased lipase inhibition in uremia: identification of pre-beta-HDL as a major inhibitor in normal and uremic plasma.
    Cheung AK; Parker CJ; Ren K; Iverius PH
    Kidney Int; 1996 May; 49(5):1360-71. PubMed ID: 8731101
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Evaluation of equilibrium gel filtration chromatography for the study of protein binding of aluminum in normal and uremic sera.
    Bertholf RL; Wills MR; Savory J
    Clin Physiol Biochem; 1985; 3(5):271-6. PubMed ID: 4053493
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Plasma proteins containing damaged L-isoaspartyl residues are increased in uremia: implications for mechanism.
    Perna AF; Castaldo P; De Santo NG; di Carlo E; Cimmino A; Galletti P; Zappia V; Ingrosso D
    Kidney Int; 2001 Jun; 59(6):2299-308. PubMed ID: 11380834
    [TBL] [Abstract][Full Text] [Related]  

  • 72. N-substituted amino acids in serum of patients with chronic renal insufficiency.
    Czerniak Z
    Clin Chim Acta; 1970 Jun; 28(3):403-8. PubMed ID: 5450164
    [No Abstract]   [Full Text] [Related]  

  • 73. Characterization of uremic "middle molecular" fractions by gas chromatography, mass spectrometry, isotachophoresis, and liquid chromatography.
    Schoots AC; Mikkers FE; Claessens HA; De Smet R; Van Landschoot N; Ringoir SM
    Clin Chem; 1982 Jan; 28(1):45-9. PubMed ID: 7055936
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Chemical analytic approaches to the definition of uremic toxins.
    Furst P; Bergstrom J; Gordon A; Zimmermann L
    Ateneo Parmense Acta Biomed; 1975; 46(5):307-16. PubMed ID: 1232992
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Influence of molecular structure on half-life and hydrolysis of dipeptides in plasma: importance of glycine as N-terminal amino acid residue.
    Adibi SA; Paleos GA; Morse EL
    Metabolism; 1986 Sep; 35(9):830-6. PubMed ID: 3747839
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Medium-sized peptides in the blood of patients with uremia.
    Mabuchi H; Nakahashi H
    Nephron; 1983; 33(4):232-7. PubMed ID: 6843753
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Uremic toxins overload accelerates renal damage in a rat model of chronic renal failure.
    Satoh M; Hayashi H; Watanabe M; Ueda K; Yamato H; Yoshioka T; Motojima M
    Nephron Exp Nephrol; 2003; 95(3):e111-8. PubMed ID: 14646363
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Effect of uremic serum and its fractions on stem cells in vivo].
    Gudim VI; Sigalla P; Ivanova VS; Moskaleva GP; Oldag K
    Biull Eksp Biol Med; 1980 May; 89(5):592-4. PubMed ID: 7397342
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Middle molecules separation from uraemic serum (author's transl)].
    Dall'aglio P; Buzio C; Gardini GP; Migone L
    Ateneo Parmense Acta Biomed; 1975; 46(5):331-44. PubMed ID: 1236694
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Purification and analysis of plasmatic components of middle molecular weight in patients with uremic syndrome.
    Martín Mateo MC; Cuevas Lobato OL; Bustamante J
    Nephron; 1995; 71(2):160-7. PubMed ID: 8569948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.